Navigation Links
Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

Results Reported From Three NCI-Sponsored Clinical Trials

SOUTH SAN FRANCISCO, CA June 28, 2007 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced results from the analyses of three Phase II clinical trials of ispinesib administered as monotherapy, one in patients with hepatocellular cancer, one in patients with melanoma, and one in patients with hormone-refractory prostate cancer. Ispinesib is a novel small molecule inhibitor of kinesin spindle protein (KSP), a mitotic kinesin essential for proper cell division. Ispinesib has arisen from a broad strategic collaboration between Cytokinetics and GlaxoSmithKline (GSK) to discover, develop and commercialize novel small molecule therapeutics targeting human mitotic kinesins for applications in the treatment of cancer and other diseases. All three clinical trials were sponsored by the National Cancer Institute (NCI).

A Phase II clinical trial designed to evaluate the safety and efficacy of ispinesib in the treatment of patients with locally advanced, recurrent or metastatic hepatocellular cancer was recently completed. In Stage 1 of this two-stage clinical trial, 15 patients received ispinesib as monotherapy at 18 mg/m2 as a 1-hour intravenous infusion every 21 days. The trial s primary endpoint was objective response as determined using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. This trial was designed to require at least 1 confirmed partial or complete response out of 15 evaluable patients in Stage 1 in order to proceed to Stage 2. The best overall response was stable disease seen in 7 of the 15 patients treated. In this clinical trial, ispinesib did not satisfy the criteria for advancement to the second stage and therefore recruitment to Stage 2 was not opened. The toxicity profile was consistent with other previously reported Phase II clinical trials of ispinesib. A manuscript is being prepared.

A Phase
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:10/22/2014)... Provectus Biopharmaceuticals, Inc. (NYSEMKT: PVCT) specializes in ... drug for cancer, is designed for injection into solid ... oncology focus is on melanoma, breast cancer and cancers ... of PV-10 as a therapy for metastatic melanoma, and ... and psoriasis. This summer, the Company ...
(Date:10/22/2014)... SHANGHAI , Oct. 22, 2014 ... ) and WuXi PharmaTech (Cayman) Inc. (NYSE: ... Medicine,s comprehensive genomic profiling to biopharmaceutical companies conducting clinical ... Under the terms of the collaboration, Foundation Medicine ... component of Foundation Medicine,s FoundationOne® assay at the WuXi ...
(Date:10/20/2014)... ENGLEWOOD, Colo. , Oct. 20, 2014 /PRNewswire/ ... Inc. (NYSE MKT: AMPE), today announced that its ... the clinical and research potential for its novel ... oxidation-reduction potential (ORP) in the body in response ... clinical value of ORP as a clinical marker ...
Breaking Medicine Technology:Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 3Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 4Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 5Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5
... , , , , ... The Heart Failure Society of America,s (HFSA) 13th Annual ... in Boston. This three-day meeting -- a forum for heart failure specialists ... trends in research and new developments in the approach to treating patients ...
... , , , ... AMGN ) today announced the presentation of data highlighting ... reduction among women with postmenopausal osteoporosis. The data were presented at ... Research (ASBMR). , , "These data enhance our ...
Cached Medicine Technology:Heart Failure Society of America 13th Annual Scientific Meeting to Focus on a Bench-To-Bedside Approach 2Heart Failure Society of America 13th Annual Scientific Meeting to Focus on a Bench-To-Bedside Approach 3Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 2Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 3Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 4Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 5Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 6Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 7Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 8Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 9
(Date:10/22/2014)... 2014 Best Cheap Hosting USA is ... The site has recently announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ... people from around the world. , “iPower is one ... and is providing various kinds of useful products for ... on offering excellent customer service and a number of ...
(Date:10/22/2014)... Although there are only 24 hours in a day, that ... trouble finding time within their busy schedules for exercise and fitness. ... time to get in shape. Here are five ways you can ... , Change Up Your Commute , Consider riding a bike or ... into your daily routine. If you must use your car to ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Akeso ... solutions for the treatment of bacterial infections, microbial biofilms, ... has joined its board of directors. , ... Engineering Systems at The Massachusetts Institute of Technology, or ... faculty since 1968. Dr. Sinskey also holds positions as ...
(Date:10/22/2014)... -- Two sisters in high school have developed ways ... Medha Krishen use electronic stethoscopes, which electronically amplify body ... patterns or heartbeats. Ilina, a senior at Port ... a way to detect early lung damage in people ... Ilina recorded one breath cycle each from 16 smokers, ...
(Date:10/22/2014)... News) -- Measures taken by Firestone officials at the ... have limited the spread of the disease there and ... Natural Rubber Co. provides health services to about 80,000 ... populated communities. Between Aug. 1 and Sept. 23, ... those 80,000 people. That incidence rate of 0.09 percent ...
Breaking Medicine News(10 mins):Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2
... 2020, Food Companies Will Be Expected to Cede Control, ... 16 Today,s consumers want to have a,greater say ... year,2020, consumers around the globe expect the way they ... a recent study of consumers in five,countries., The ...
... FALLS CHURCH, Va., Oct. 16 Between ... digestive health issue (*see reference,below). The issue may ... prebiotics and probiotics could benefit them. For this ... prebiotics and,probiotics by working with a truly innovative ...
... Americans United for Life,(AUL) today filed an amicus ... of the deadly abortion drug, RU-486., AUL President ... of ruining and even ending women,s lives. We must ... drug. Ohio,s statute is a,step in the right direction, ...
... and Rockville, Md., SAN JOSE, Calif., Oct. ... fundraising events for the Coalition for Pulmonary,Fibrosis (CPF) ... the,CPF collectively raised more than a half million ... fighting pulmonary fibrosis (PF) and,directly funds research. The ...
... stories of,Louisiana women and others across the South, ... of,people living with AIDS in Louisiana are minorities, ... African American women ages 25-34 today. On,Wednesday, October ... for Life,will launch the Southern AIDS Living Quilt ...
... attend the annual meeting of the Big Sky Carbon ... in Spokane, Wash. , The meeting will address key ... carbon capture and storage (CCS). Panels of experts will ... economics of CCS, regulatory and mitigation procedures, energy policies, ...
Cached Medicine News:Health News:New Study Reveals Consumers Want Greater Say in Key Food Issues 2Health News:New Study Reveals Consumers Want Greater Say in Key Food Issues 3Health News:New Study Reveals Consumers Want Greater Say in Key Food Issues 4Health News:New Study Reveals Consumers Want Greater Say in Key Food Issues 5Health News:MyHealthGate, Inc. Joins With LiveActive Chewy Granola Bars to Raise Digestive Health Awareness 2Health News:Ohio's Regulation of RU-486 Clear and Constitutional, Should Be Upheld Argues AUL in Brief Filed Before Ohio Supreme Court 2Health News:CPF Fundraisers Bring in Landmark Half Million Dollars in Less Than Three Weeks 2Health News:CPF Fundraisers Bring in Landmark Half Million Dollars in Less Than Three Weeks 3Health News:Southern AIDS Living Quilt Project Launch to Break Down Barriers 2
Latex agglutination test for the qualitative and semiquantitative determination of rheumatoid factor in serum....
RFScan Latex Test Kit-100...
... Specialty / Drug Clinical System is ... consolidate Drugs of Abuse, TDM's and ... HbA1c and lipids in one convenient ... level of automation and flexibility previously ...
... systems are fully automated to ... turnaround of highly accurate specific ... monitoring (TDM) results. Using unique ... easy-to-use Array® 360 performs a ...
Medicine Products: